OBJECTIVE: To investigate the effect of vitamin D3 supplementation on the incidence and risk for first and recurrent diarrheal illnesses among children in Kabul, Afghanistan. METHODS: This double-blind placebo-controlled trial randomized 3046 high-risk 1- to 11-month-old infants to receive 6 quarterly doses of oral vitamin D3 (cholecalciferol 100000 IU) or placebo in inner city Kabul. Data on diarrheal episodes (≥ 3 loose/liquid stools in 24 hours) was gathered through active and passive surveillance over 18 months of follow-up. Time to first diarrheal illness was analyzed by using Kaplan-Meier plots. Incidence rates and hazard ratios (HRs) were calculated by using recurrent event Poisson regression models. RESULTS: No significant difference existed in survival time to first diarrheal illness (log rank P = .55). The incidences of diarrheal episodes were 3.43 (95% confidence interval [CI], 3.28-3.59) and 3.59 per child-year (95% CI, 3.44-3.76) in the placebo and intervention arms, respectively. Vitamin D3 supplementation was found to have no effect on the risk for recurrent diarrheal disease in either intention-to-treat (HR, 1.05; 95% CI, 0.98-1.17; P = .15) or per protocol (HR, 1.05; 95% CI, 0.98-1.12; P = .14) analyses. The lack of preventive benefit remained when the randomized population was stratified by age groups, nutritional status, and seasons. CONCLUSIONS: Quarterly supplementation with vitamin D3 conferred no reduction on time to first illness or on the risk for recurrent diarrheal disease in this study. Similar supplementation to comparable populations is not recommended. Additional research in alternative settings may be helpful in elucidating the role of vitamin D3 supplementation for prevention of diarrheal diseases.
RCT Entities:
OBJECTIVE: To investigate the effect of vitamin D3 supplementation on the incidence and risk for first and recurrent diarrheal illnesses among children in Kabul, Afghanistan. METHODS: This double-blind placebo-controlled trial randomized 3046 high-risk 1- to 11-month-old infants to receive 6 quarterly doses of oral vitamin D3 (cholecalciferol 100000 IU) or placebo in inner city Kabul. Data on diarrheal episodes (≥ 3 loose/liquid stools in 24 hours) was gathered through active and passive surveillance over 18 months of follow-up. Time to first diarrheal illness was analyzed by using Kaplan-Meier plots. Incidence rates and hazard ratios (HRs) were calculated by using recurrent event Poisson regression models. RESULTS: No significant difference existed in survival time to first diarrheal illness (log rank P = .55). The incidences of diarrheal episodes were 3.43 (95% confidence interval [CI], 3.28-3.59) and 3.59 per child-year (95% CI, 3.44-3.76) in the placebo and intervention arms, respectively. Vitamin D3 supplementation was found to have no effect on the risk for recurrent diarrheal disease in either intention-to-treat (HR, 1.05; 95% CI, 0.98-1.17; P = .15) or per protocol (HR, 1.05; 95% CI, 0.98-1.12; P = .14) analyses. The lack of preventive benefit remained when the randomized population was stratified by age groups, nutritional status, and seasons. CONCLUSIONS: Quarterly supplementation with vitamin D3 conferred no reduction on time to first illness or on the risk for recurrent diarrheal disease in this study. Similar supplementation to comparable populations is not recommended. Additional research in alternative settings may be helpful in elucidating the role of vitamin D3 supplementation for prevention of diarrheal diseases.
Entities:
Keywords:
Afghanistan; children; diarrhea prevention; vitamin D supplementation
Authors: Alexandra V Yamshchikov; Nirali S Desai; Henry M Blumberg; Thomas R Ziegler; Vin Tangpricha Journal: Endocr Pract Date: 2009 Jul-Aug Impact factor: 3.443
Authors: Alison Talbert; Nahashon Thuo; Japhet Karisa; Charles Chesaro; Eric Ohuma; James Ignas; James A Berkley; Christopher Toromo; Sarah Atkinson; Kathryn Maitland Journal: PLoS One Date: 2012-06-04 Impact factor: 3.240
Authors: Christa L Fischer Walker; Jamie Perin; Martin J Aryee; Cynthia Boschi-Pinto; Robert E Black Journal: BMC Public Health Date: 2012-03-21 Impact factor: 3.295
Authors: Giuseppe Saggese; Francesco Vierucci; Flavia Prodam; Fabio Cardinale; Irene Cetin; Elena Chiappini; Gian Luigi De' Angelis; Maddalena Massari; Emanuele Miraglia Del Giudice; Michele Miraglia Del Giudice; Diego Peroni; Luigi Terracciano; Rino Agostiniani; Domenico Careddu; Daniele Giovanni Ghiglioni; Gianni Bona; Giuseppe Di Mauro; Giovanni Corsello Journal: Ital J Pediatr Date: 2018-05-08 Impact factor: 2.638
Authors: A M S Ahmed; R J S Magalhaes; T Ahmed; K Z Long; MdI Hossain; M M Islam; M Mahfuz; S M A Gaffar; A Sharmeen; R Haque; R L Guerrant; W A Petri; A A Mamun Journal: Eur J Clin Nutr Date: 2016-03-09 Impact factor: 4.016
Authors: Adam R Aluisio; Zabihullah Maroof; Daniel Chandramohan; Jane Bruce; Mohammad I Masher; Semira Manaseki-Holland; Jeroen H J Ensink Journal: PLoS One Date: 2015-02-13 Impact factor: 3.240
Authors: Christine Kim; Ghulam Farooq Mansoor; Pir Mohammad Paya; Mohammad Homayoun Ludin; Mohammad Javed Ahrar; Mohammad Omar Mashal; Catherine S Todd Journal: Health Res Policy Syst Date: 2020-06-11